89bio Inc (ETNB)

New York State Common Retirement Fund Boosts Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World

Defense World

Insider Selling: PALEKAR ROHAN, 89bio Inc [ETNB] Chief Executive Officer divested 52718 shares – Knox Daily - Knox Daily

Knox Daily

89bio (NASDAQ:ETNB) Stock Rating Reaffirmed by HC Wainwright - MarketBeat

MarketBeat

Cantor Fitzgerald Comments on 89bio, Inc.'s FY2024 Earnings (NASDAQ:ETNB) - Defense World

Defense World

89bio (NASDAQ:ETNB) Trading Up 5.5% - MarketBeat

MarketBeat

89bio, Inc. (NASDAQ:ETNB) to Post FY2024 Earnings of ($2.30) Per Share, Cantor Fitzgerald Forecasts - MarketBeat

MarketBeat

89bio (NASDAQ:ETNB) Price Target Cut to $33.00 by Analysts at Evercore ISI - MarketBeat

MarketBeat

Is it possible to buy 89bio Inc(ETNB) shares at a good price now? – US Post News - US Post News

US Post News

89bio shares target cut to $33 on higher expenses - Investing.com

Investing.com

89bio, Inc. (NASDAQ:ETNB) insider upped their holding by 23% earlier this year - Yahoo New Zealand News

Yahoo New Zealand News

Gaining Ground: 89bio Inc (ETNB) Closes Lower at 8.70, Down -0.11 – DWinneX - The Dwinnex

The Dwinnex

A new trading data show 89bio Inc (ETNB) is showing positive returns. – Sete News - SETE News

SETE News

89bio (NASDAQ:ETNB) Price Target Cut to $29.00 - Defense World

Defense World

BofA Securities's latest rating for ETNB stock – Knox Daily - Knox Daily

Knox Daily

89bio shares target cut, maintains buy rating By Investing.com - Investing.com

Investing.com

89bio (NASDAQ:ETNB) Price Target Lowered to $29.00 at HC Wainwright - MarketBeat

MarketBeat

89bio (NASDAQ:ETNB) Issues Earnings Results - MarketBeat

MarketBeat

(ETNB) Trading Signals - Stock Traders Daily

Stock Traders Daily

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WICZ

WICZ

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

RBC Capital cuts 89bio shares target on model adjustments - Investing.com

Investing.com

Zurcher Kantonalbank Zurich Cantonalbank Purchases 7692 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World

Defense World

Views of Wall Street's Leading Experts on 89bio Inc – Sete News - SETE News

SETE News

New Strong Sell Stocks for January 21st - Yahoo Movies UK

Yahoo Movies UK

Latest Insider moments: PALEKAR ROHAN, 89bio Inc [ETNB] Chief Executive Officer sold 52718 shares – Knox Daily - Knox Daily

Knox Daily

All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy - Zacks Investment Research

Zacks Investment Research

All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy - Yahoo Finance UK

Yahoo Finance UK

89bio, Inc. (NASDAQ:ETNB) insider upped their holding by 23% earlier this year - Yahoo New Zealand News

Yahoo New Zealand News

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH - ForexTV.com

ForexTV.com

(ETNB) On The My Stocks Page - Stock Traders Daily

Stock Traders Daily

An Analysis of 89bio Inc (ETNB)'s Potential Price Growth – Knox Daily - Knox Daily

Knox Daily

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

GlobeNewswire Inc.

89bio adds biotech veteran Martin Babler to board By Investing.com - Investing.com

Investing.com

PRIME Scheme: EMA Says Yes To Hookipa, Bluejay & 89bio But No To Six Others - Pink Sheet

Pink Sheet

89bio signs deal for construction of a production facility in China (NASDAQ:ETNB) - Seeking Alpha

Seeking Alpha

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

89bio CEO Rohan Palekar trades over $620k in company stock - Investing.com

Investing.com

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

GlobeNewswire Inc.

89bio wins EMA priority status for MASH candidate pegozafermin - Pharmaceutical Technology

Pharmaceutical Technology

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

The Motley Fool

Madrigal’s stock surges as FDA approves first drug for liver disease MASH

MarketWatch

Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH

MarketWatch

89bio kicks off Phase III trial for pegozafermin in MASH - Clinical Trials Arena

Clinical Trials Arena

Buffett Loads Up on This Stock Again, Plus CEO Insider Buying - 24/7 Wall St.

24/7 Wall St.

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

Benzinga

Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Markets Insider

Markets Insider

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

Zacks Investment Research

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

Zacks Investment Research

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade

Zacks Investment Research